• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Connect Biopharma Holdings Ltd ADR (NQ: CNTB )

    1.180 +0.020 (+1.72%)
    Streaming Delayed Price Updated: 11:59 AM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Connect Biopharma Holdings Ltd ADR

    < Previous 1 2 Next >
    Attovia Therapeutics Appoints Chief Financial Officer
    Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer 
    From Attovia Therapeutics, Inc.
    Via GlobeNewswire
    Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Announces New Leadership and Chair of the Board of Directors
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
    Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... 
    Via Newsfile
    Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma to Participate in Upcoming September Investor Conferences
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
    From Connect Biopharma Holdings Limited
    Via Business Wire
    Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
    From Connect Biopharma Holdings Limited
    Via Business Wire
    Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
    From Connect Biopharma Holdings Limited
    Via Business Wire
    Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.